(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Easy to understand Tech: Cell phones for Old in 2024 - 2Argentina joins NASA’s moon return with microsatellite testing GPS beyond Earth
- 3How does Spotify Wrapped calculate your listening age? What your number says about you.
- 4Help Your Efficiency: 10 Authoritative Apparatuses to Attempt
- 5From ‘Project Hail Mary’ to Artemis II, spaceflight captures audiences when it centers on people because human space travel is hazardous
- In the stomach of a mummified wolf pup, scientists find DNA from a woolly rhinoceros
- Flash flooding causes highways to close to and from Eilat
- Windows to the Previous: An Excursion Through the World's Notable Engineering
- What really happens when 140 reality stars come face to face with their biggest fans
- Savvy Tips for Seniors Hyundai IONIQ EV
- CDC changes kids' vaccine schedule, removing universal recommendation for some shots
- Pick Your #1 Kind Of Bread
- When is MLK Day? Plus, the dates of when other federal holidays land in 2026.
- Before trips to Mars, we need better protection from cosmic rays
